Bayraktar Y, Uzunalimoglu B, Arslan S, Koseoglu T, Kayhan B, Telatar H
Hacettepe University Hospital, School of Medicine, Department of Gastroenterology, Ankara, Turkey.
Gut. 1993;34(2 Suppl):S101. doi: 10.1136/gut.34.2_suppl.s101.
This paper presents the preliminary results of a study designed to evaluate the effects of alpha interferon in chronic hepatitis B. After six months' treatment with interferon alfa-2b (5 million units (MU), three times weekly) 15 of 25 (60%) patients achieved seroconversion of hepatitis B e antigen, 17 (68%) normalised alanine aminotransferase (ALT) activity, and 15 (60%) showed a decrease in the inflammatory reaction on liver histology. No seroconversions occurred in the control group (n = 10), and none of the control patients achieved a normal ALT or showed a reduction in the inflammatory reaction. Adverse effects were experienced by most patients who received interferon but none warranted stopping the treatment.
本文介绍了一项旨在评估α干扰素对慢性乙型肝炎疗效的研究的初步结果。用α-2b干扰素（500万单位，每周3次）治疗6个月后，25例患者中有15例（60%）实现了乙肝e抗原血清学转换，17例（68%）丙氨酸转氨酶（ALT）活性恢复正常，15例（60%）肝脏组织学炎症反应减轻。对照组（n = 10）未发生血清学转换，且对照组患者均未实现ALT正常或炎症反应减轻。大多数接受干扰素治疗的患者出现了不良反应，但均无需停药。
